{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:24:18Z","timestamp":1790907858008,"version":"4.1.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2018,6,8]],"date-time":"2018-06-08T00:00:00Z","timestamp":1528416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"},{"start":{"date-parts":[[2018,6,8]],"date-time":"2018-06-08T00:00:00Z","timestamp":1528416000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,9,1]]},"DOI":"10.1002\/ejhf.1217","type":"journal-article","created":{"date-parts":[[2018,6,8]],"date-time":"2018-06-08T06:00:34Z","timestamp":1528437634000},"page":"1247-1251","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Need to Revisit Heart Failure Treatment Guidelines for Hyperkalaemia Management During the Use of Mineralocorticoid Receptor Antagonists"],"prefix":"10.1093","volume":"20","author":[{"given":"Javed","family":"Butler","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Stony Brook University , Stony Brook, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Vijayakumar","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Stony Brook University , Stony Brook, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, University of Michigan , Ann Arbor, MI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,6,8]]},"reference":[{"key":"2026011721250274900_ejhf1217-bib-0001","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026011721250274900_ejhf1217-bib-0002","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2026011721250274900_ejhf1217-bib-0003","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"2026011721250274900_ejhf1217-bib-0004","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2026011721250274900_ejhf1217-bib-0005","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"2026011721250274900_ejhf1217-bib-0006","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.cardfail.2003.10.012","article-title":"How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?","volume":"10","author":"Svensson","year":"2004","journal-title":"J Card Fail"},{"key":"2026011721250274900_ejhf1217-bib-0007","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12872-016-0198-2","article-title":"Efficacy and safety of mineralocorticoid receptor antagonists for patients with heart failure and diabetes mellitus: a systematic review and meta-analysis","volume":"16","author":"Chen","year":"2016","journal-title":"BMC Cardiovasc Disord"},{"key":"2026011721250274900_ejhf1217-bib-0008","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N Engl J Med"},{"key":"2026011721250274900_ejhf1217-bib-0009","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.cardfail.2012.02.005","article-title":"Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee","volume":"18","author":"Butler","year":"2012","journal-title":"J Card Fail"},{"key":"2026011721250274900_ejhf1217-bib-0010","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026011721250274900_ejhf1217-bib-0011","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1161\/CIRCHEARTFAILURE.114.001104","article-title":"Randomized Aldactone Evaluation Study (RALES) Investigators. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist","volume":"7","author":"Vardeny","year":"2014","journal-title":"Circ Heart Fail"},{"key":"2026011721250274900_ejhf1217-bib-0012","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/CIRCHEARTFAILURE.113.000792","article-title":"Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)","volume":"7","author":"Rossignol","year":"2014","journal-title":"Circ Heart Fail"},{"key":"2026011721250274900_ejhf1217-bib-0013","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1001\/jama.2011.1967","article-title":"Serum potassium levels and mortality in acute myocardial infarction","volume":"307","author":"Goyal","year":"2012","journal-title":"JAMA"},{"key":"2026011721250274900_ejhf1217-bib-0014","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/ehjcvp\/pvv026","article-title":"Short-term mortality risk of serum potassium levels in acute heart failure following myocardial infarction","volume":"1","author":"Krogager","year":"2015","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026011721250274900_ejhf1217-bib-0015","first-page":"104","article-title":"Short-term mortality risk of serum potassium levels in hypertension: a retrospective analysis of nationwide registry data","volume":"38","author":"Krogager","year":"2017","journal-title":"Eur Heart J"},{"key":"2026011721250274900_ejhf1217-bib-0016","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1093\/eurheartj\/ehx460","article-title":"Associations of serum potassium levels with mortality in chronic heart failure patients","volume":"38","author":"Aldahl","year":"2017","journal-title":"Eur Heart J"},{"key":"2026011721250274900_ejhf1217-bib-0017","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1161\/CIRCULATIONAHA.117.030576","article-title":"Long-term potassium monitoring and dynamics in heart failure and risk of mortality","volume":"137","author":"Nunez","year":"2018","journal-title":"Circulation"},{"key":"2026011721250274900_ejhf1217-bib-0018","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000479802","article-title":"Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and\/or diabetes","volume":"46","author":"Collins","year":"2017","journal-title":"Am J Nephrol"},{"key":"2026011721250274900_ejhf1217-bib-0019","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1016\/j.amjcard.2016.08.078","article-title":"Serum potassium levels and outcome in patients with chronic heart failure","volume":"118","author":"Hoss","year":"2016","journal-title":"Am J Cardiol"},{"key":"2026011721250274900_ejhf1217-bib-0020","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.amjcard.2016.09.038","article-title":"Serum potassium levels and outcome in acute heart failure (data from the PROTECT and COACH trials)","volume":"119","author":"Tromp","year":"2017","journal-title":"Am J Cardiol"},{"key":"2026011721250274900_ejhf1217-bib-0021","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.amjcard.2014.12.045","article-title":"Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction (from the EVEREST trial)","volume":"115","author":"Khan","year":"2015","journal-title":"Am J Cardiol"},{"key":"2026011721250274900_ejhf1217-bib-0022","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.ahj.2015.06.003","article-title":"Serum potassium decline during hospitalization for acute decompensated heart failure is a predictor of 6-month mortality, independent of N-terminal pro-B-type natriuretic peptide levels: an individual patient data analysis","volume":"170","author":"Salah","year":"2015","journal-title":"Am Heart J"},{"key":"2026011721250274900_ejhf1217-bib-0023","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/ejhf.402","article-title":"Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors","volume":"17","author":"Pitt","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026011721250274900_ejhf1217-bib-0024","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1001\/jama.289.7.871","article-title":"Association of serum digoxin concentration and outcomes in patients with heart failure","volume":"289","author":"Rathore","year":"2003","journal-title":"JAMA"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fejhf.1217","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/20\/9\/1247\/66268289\/eurjhf_20_9_1247.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/20\/9\/1247\/66268289\/eurjhf_20_9_1247.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T02:27:22Z","timestamp":1768703242000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/20\/9\/1247\/8414582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,8]]},"references-count":24,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2018,6,8]]},"published-print":{"date-parts":[[2018,9,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.1217","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,9]]},"published":{"date-parts":[[2018,6,8]]},"assertion":[{"value":"2018-01-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}